Seagen is dedicated to revolutionizing cancer care and improving patient outcomes with small-molecule technologies.
Employees: 1001-5000
Founded date: 1998
Investors 2
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 9
| Date | Title | Description |
| 22.03.2018 | Seattle Genetics lands fifth Adcetris approval as investors shrug | Seattle Genetics reaped $30.7.6 million in sales of Adcetris in 2017 and some analysts predict that the fifth time’s the charm for driving that number to $1 billion and beyond. Despite that potential, the company’s shares were down 1.56 per... |
| 20.03.2017 | BMS signs new $200M licensing deal for CytomX probodies | It builds on a similar agreement announced in 2014, which saw BMS license up to four candidates for an initial $50 million and $1.2 billion in possible royalties. As the millions add up, would it have more efficient for BMS to acquire the 2... |
| 10.02.2017 | Seattle Genetics signs $2B deal for solid tumor ADC | According to Clay Siegall, CEO of Seattle Genetics, the milestones stretch out for many years and are contingent upon approvals in different jurisdictions and in indications beyond breast cancer. “I honestly, would love to pay out all the m... |
| 14.08.2016 | Major drug partnership aims to develop new cancer drug | Helsinn assumes worldwide development costs and marketing rights for MEI Pharma’s drug and gains a foothold in the cancer therapeutics market. MEI receives $20 million in near-term payments with the potential for $444 million in various mil... |
| 12.07.2007 | Agensys pulls in $41M for cancer drugs | Santa Monica, Calif.-based Agensys, a biotech focused on new cancer drugs, raised $41 million in a fourth funding round. Duquesne Capital Management and JAFCO led the round, joined by Innovis Investments, Nextech Venture, Bear Stearns Healt... |
| - | BMS signs new $200M licensing deal for CytomX probodies | Bristol-Myers Squibb (BMS) is back for seconds, dropping $200 million for up to eight more “probody” drug candidates from CytomX Therapeutics. Announced Monday, the deal also outlines a potential boost of “up to $448 million in future devel... |
| - | Major drug partnership aims to develop new cancer drug | A recent cancer partnership worth hundreds of millions of dollars aims to develop a drug to contend with acute myeloid leukemia. San Diego-based MEI Pharma has inked a deal with Swiss firm Helsinn to develop and market its HDAC (the class o... |
| - | Seattle Genetics lands fifth Adcetris approval as investors shrug | Seattle Genetics has landed its fifth approval for the drug Adcetris (brentuximab vedotin), for classical stage III or stage IV Hodgkin lymphoma. The indication is for use in combination with chemotherapy for previously untreated disease. T... |
| - | Seattle Genetics signs $2B deal for solid tumor ADC | Seattle Genetics has secured global rights to Immunomedics’ antibody-drug conjugate IMMU-132 (sacituzumab govitecan), currently in late-stage trials for triple-negative metastatic breast cancer. Immunomedics could receive up to $2 billion i... |